Last reviewed · How we verify
Vancomycin or Fidaxomicin
Vancomycin and Fidaxomicin are antibiotics that inhibit bacterial cell wall synthesis or protein synthesis to treat Clostridioides difficile infections.
Vancomycin and Fidaxomicin are antibiotics that inhibit bacterial cell wall synthesis or protein synthesis to treat Clostridioides difficile infections. Used for Clostridioides difficile-associated diarrhea (CDAD), Recurrent C. difficile infection.
At a glance
| Generic name | Vancomycin or Fidaxomicin |
|---|---|
| Sponsor | Sejtterapia Kozpont Kft. |
| Drug class | Antibiotic (Glycopeptide / Macrocyclic) |
| Target | Bacterial cell wall (Vancomycin) / Bacterial RNA polymerase (Fidaxomicin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, while Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase. Both are used to treat C. difficile-associated diarrhea (CDAD), with Fidaxomicin showing lower recurrence rates due to minimal systemic absorption and targeted local activity in the colon.
Approved indications
- Clostridioides difficile-associated diarrhea (CDAD)
- Recurrent C. difficile infection
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
Key clinical trials
- Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy (EARLY_PHASE1)
- Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence (PHASE3)
- STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection (NA)
- A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) (PHASE3)
- Clostridioides Difficile and Frailty (NA)
- Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) (PHASE3)
- Bezlotoxumab Versus FMT for Multiple Recurrent CDI (PHASE4)
- Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancomycin or Fidaxomicin CI brief — competitive landscape report
- Vancomycin or Fidaxomicin updates RSS · CI watch RSS
- Sejtterapia Kozpont Kft. portfolio CI